Autolus Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Total Funding:$281.7M
Industry:Biotech
Founded:2014
Lead Investor(s):N/A

Industry Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Autolus's estimated annual revenue is currently $66.2M per year.
  • Autolus's estimated revenue per employee is $155,000
  • Autolus's total funding is $281.7M.

Employee Data

  • Autolus has 427 Employees.
  • Autolus grew their employee count by 21% last year.
  • Autolus currently has 8 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
#1
$46.5M300N/AN/A-N/A
#2
$29.1M188N/AN/A-N/A
#3
$16.7M108N/AN/A-N/A
#4
$35.7M230N/AN/A-N/A
#5
$26.8M173N/AN/A-N/A
#6
$58.9M380N/AN/A-N/A
#7
$20.2M130N/AN/A-N/A
#8
$23.7M153N/AN/A-N/A
#9
$21.7M140N/AN/A-N/A
#10
$24.8M160N/AN/A-N/A
Missing a competitor? Contribute!?
Submit

Autolus is a private biopharmaceutical company, focused on the development and commercialisation of engineered T-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. We are building a leading biotechnology company focussed on the development and commercialisation of engineered T-cell therapies for haematological and solid tumours. Autolus has the ambition to be a leader of a revolution in medicine in which life-threatening diseases are treated by a patient's own cells.

keywords:N/A

427

Number of Employees

$66.2M

Revenue (est)

8

Current Jobs

21%

Employee Growth %

$281.7M

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Autolus News

09/03/2019 - Arix jumps as Woodford finally sells stake in Autolus Therapeutics

In a note, analysts at US broker Stifel noted a large block trade of 7.4mln Autolus shares on Thursday could only have come from the Woodford ...

09/08/2019 - Do Analysts Recommend You Should Buy Autolus Therapeutics plc (AUTL) Stock?

On Thursday, shares of Autolus Therapeutics plc (NASDAQ:AUTL) marked $11.93 per share versus a previous $9.80 closing price. With having ...

09/03/2019 - Autolus Therapeutics Plc (AUTL) Q2 2019 Earnings Call Transcript

Good morning, ladies and gentlemen, and welcome to the Autolus Therapeutics second-quarter 2019 financial results conference call.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
#1
$93.9M4276%N/A-N/A
#2
$62.2M42911%N/A3/5N/A
#3
$71M430N/AN/A-N/A
#4
$88.2M430N/AN/A-N/A
#5
$90.3M430N/AN/A-N/A